---
title: "Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296122142.md"
description: "Exelixis reported second-quarter revenue of about $628.7 million, falling below the Wall Street consensus, leading to a drop in share prices during after-hours trading. Levi & Korsinsky has initiated an investigation in response. The revenue miss, rather than an earnings miss, was the main factor driving the situation for Exelixis, Inc. In New York on August 17, 2026."
datetime: "2026-08-17T14:21:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296122142.md)
  - [en](https://longbridge.com/en/news/296122142.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296122142.md)
generator: "portal-rs"
---

# Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky

Exelixis reported second-quarter revenue of about $628.7 million, falling below the Wall Street consensus, leading to a drop in share prices during after-hours trading. Levi & Korsinsky has initiated an investigation in response. The revenue miss, rather than an earnings miss, was the main factor driving the situation for Exelixis, Inc. In New York on August 17, 2026.

### Related Stocks

- [EXEL.US](https://longbridge.com/en/quote/EXEL.US.md)

## Related News & Research

- [Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In](https://longbridge.com/en/news/298761132.md)
- [Exelixis NDA review for zanzalintinib plus atezolizumab extended; PDUFA date moved to Mar 3, 2027](https://longbridge.com/en/news/298721674.md)
- [EXEL: CABO and zanza drive growth, with immediate CRC launch readiness and robust pipeline plans](https://longbridge.com/en/news/298348812.md)
- [Analysts’ Opinions Are Mixed on These NA Stocks: SpaceX (SPCX), Insmed (INSM) and Exelixis (EXEL)](https://longbridge.com/en/news/298816579.md)
- [Allianz Asset Management GmbH Decreases Holdings in Exelixis, Inc. $EXEL](https://longbridge.com/en/news/298276045.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**